Scynexis is a drug manufacturers - specialty & generic business based in the US. Scynexis shares (SCYX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.23 – a decrease of 12.77% over the previous week. Scynexis employs 29 staff and has a trailing 12-month revenue of around $8.6 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.23 |
|---|---|
| 52-week range | $0.90 - $3.07 |
| 50-day moving average | $1.23 |
| 200-day moving average | $1.65 |
| Wall St. target price | $6.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.23 from 2025-01-10
| 1 week (2025-01-03) | -12.77% |
|---|---|
| 1 month (2024-12-13) | 7.89% |
| 3 months (2024-10-11) | -19.61% |
| 6 months (2024-07-12) | -44.09% |
| 1 year (2024-01-12) | -37.88% |
|---|---|
| 2 years (2023-01-12) | -32.79% |
| 3 years (2022-01-12) | 5.67 |
| 5 years (2020-01-10) | 10.2 |
| Revenue TTM | $8.6 million |
|---|---|
| Gross profit TTM | $12.9 million |
| Return on assets TTM | -26.72% |
| Return on equity TTM | -48.42% |
| Profit margin | 0% |
| Book value | $1.54 |
| Market Capitalization | $46.7 million |
TTM: trailing 12 months
We're not expecting Scynexis to pay a dividend over the next 12 months.
Scynexis's shares were split on a 1:10 basis on 16 July 2020 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Scynexis shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Scynexis shares which in turn could have impacted Scynexis's share price.
Over the last 12 months, Scynexis's shares have ranged in value from as little as $0.9006 up to $3.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Scynexis's is 1.503. This would suggest that Scynexis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
SCYNEXIS, Inc. , a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Access remote advice, planning and portfolio management from this established financial services company.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2025.
This account boasts commission-free trades and no minimums but has a low cash sweep rate.